View Future GrowthAspira Pathlab & Diagnostics 過去の業績過去 基準チェック /26Aspira Pathlab & Diagnosticsの収益は年間平均-21%の割合で減少していますが、 Healthcare業界の収益は年間 増加しています。収益は年間25.3% 7.4%割合で 増加しています。 Aspira Pathlab & Diagnosticsの自己資本利益率は0.4%であり、純利益率は0.2%です。主要情報-20.95%収益成長率-24.30%EPS成長率Healthcare 業界の成長29.41%収益成長率7.40%株主資本利益率0.42%ネット・マージン0.21%前回の決算情報31 Mar 2026最近の業績更新お知らせ • May 18Aspira Pathlab & Diagnostics Limited to Report Q4, 2026 Results on May 23, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 23, 2026Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹1.52 loss per share (vs ₹0.30 profit in 3Q 2025)Third quarter 2026 results: ₹1.52 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹52.5m (down 2.9% from 3Q 2025). Net loss: ₹15.6m (down ₹18.7m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 04Aspira Pathlab & Diagnostics Limited to Report Q3, 2026 Results on Feb 10, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2026 results on Feb 10, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹1.78 (vs ₹0.30 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.78 (up from ₹0.30 in 2Q 2025). Revenue: ₹82.3m (up 52% from 2Q 2025). Net income: ₹18.4m (up 500% from 2Q 2025). Profit margin: 22% (up from 5.7% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 04Aspira Pathlab & Diagnostics Limited to Report Q2, 2026 Results on Nov 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2026 results on Nov 12, 2025Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.41 (up from ₹0.05 in 1Q 2025). Revenue: ₹53.6m (up 16% from 1Q 2025). Net income: ₹4.22m (up ₹3.74m from 1Q 2025). Profit margin: 7.9% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.すべての更新を表示Recent updatesNew Risk • May 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.2% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.2% net profit margin). Revenue is less than US$5m (₹255m revenue, or US$2.7m). Market cap is less than US$100m (₹1.17b market cap, or US$12.2m).お知らせ • May 18Aspira Pathlab & Diagnostics Limited to Report Q4, 2026 Results on May 23, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 23, 2026Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹77.07, the stock trades at a trailing P/E ratio of 55.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 141% over the past three years.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹64.74, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 97% over the past three years.New Risk • Mar 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$10m (₹644.1m market cap, or US$7.01m). Minor Risk Revenue is less than US$5m (₹242m revenue, or US$2.6m).お知らせ • Mar 07Aspira Pathlab & Diagnostics Limited Announces Resignation of Krupali Shah as Company Secretary Cum Compliance Officer, Effective March 8, 2026Aspira Pathlab & Diagnostics Limited has announced that Ms. Krupali Shah, (Membership No: A70473) Company Secretary cum Compliance Officer of the Company has tendered her resignation due to personal reasons and she will be relieved from her services with effect from March 8, 2026.Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹1.52 loss per share (vs ₹0.30 profit in 3Q 2025)Third quarter 2026 results: ₹1.52 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹52.5m (down 2.9% from 3Q 2025). Net loss: ₹15.6m (down ₹18.7m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 07Aspira Pathlab & Diagnostics Limited Appoints Kiran Raghavendra Awasthi as Non-Executive, Independent Director Effective November 12, 2025Aspira Pathlab & Diagnostics Limited has appointed Mrs. Kiran Raghavendra Awasthi (DIN: 09066721) as Non-Executive, Independent Director for the first term of five consecutive years with effect from November 12, 2025. The appointment was approved by the members of the company through Postal Ballot (remote e-voting) by a Special Resolution. Mrs. Kiran Awasthi is a Chartered Accountant and is a senior partner at AMRG & Associates with over 28 years of experience in the field of Finance, Audit, Accounting & Taxation. She also serves on Board of Raj Oil Mills Limited as Independent Director. She has wide and rich exposure in financial management, governance and analytical leadership with a strong commitment to professionalism and integrity.お知らせ • Feb 04Aspira Pathlab & Diagnostics Limited to Report Q3, 2026 Results on Feb 10, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2026 results on Feb 10, 2026お知らせ • Jan 05Aspira Pathlab & Diagnostics Limited Announces Demise of Independent Director Dr. Alaka Keshav Deshpande and Changes in Board Committee Composition, Effective on December 30, 2025Aspira Pathlab & Diagnostics Limited announced the demise of Dr. Alaka Keshav Deshpande, Independent Director aged 79 years, who passed away on December 30, 2025. Owing to the unfortunate demise of Dr. Alaka Keshav Deshpande, she ceases from the office of Independent Director of the Company effective from December 30, 2025 and also ceases the Membership held in the following Committees of Board: Audit Committee - Member, Nomination & Remuneration Committee - Member, Stakeholder Relationship Committee - Member.Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹1.78 (vs ₹0.30 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.78 (up from ₹0.30 in 2Q 2025). Revenue: ₹82.3m (up 52% from 2Q 2025). Net income: ₹18.4m (up 500% from 2Q 2025). Profit margin: 22% (up from 5.7% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 04Aspira Pathlab & Diagnostics Limited to Report Q2, 2026 Results on Nov 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2026 results on Nov 12, 2025Valuation Update With 7 Day Price Move • Oct 03Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹71.68, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 45x in the Healthcare industry in India. Total returns to shareholders of 57% over the past three years.New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹702.7m market cap, or US$7.92m). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Revenue is less than US$5m (₹226m revenue, or US$2.5m).お知らせ • Sep 26Aspira Pathlab & Diagnostics Limited Appoints Dr. Alaka Deshpande as Independent DirectorAspira Pathlab & Diagnostics Limited announced that at its AGM held on September 26, 2025, shareholders approved the appointment of Dr. Alaka Deshpande as independent director for the term of 3 years.お知らせ • Sep 01Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025, at 14:00 Indian Standard Time.Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.41 (up from ₹0.05 in 1Q 2025). Revenue: ₹53.6m (up 16% from 1Q 2025). Net income: ₹4.22m (up ₹3.74m from 1Q 2025). Profit margin: 7.9% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Aug 02Aspira Pathlab & Diagnostics Limited to Report Q1, 2026 Results on Aug 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2026 results on Aug 12, 2025Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹61.95, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹61.80, the stock trades at a trailing P/E ratio of 31.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years.Reported Earnings • May 20Full year 2025 earnings released: EPS: ₹1.97 (vs ₹2.60 loss in FY 2024)Full year 2025 results: EPS: ₹1.97 (up from ₹2.60 loss in FY 2024). Revenue: ₹223.9m (up 70% from FY 2024). Net income: ₹20.2m (up ₹46.9m from FY 2024). Profit margin: 9.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹548.1m market cap, or US$6.41m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (₹200m revenue, or US$2.3m).お知らせ • May 10Aspira Pathlab & Diagnostics Limited to Report Q4, 2025 Results on May 16, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2025 results on May 16, 2025Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.72 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.30 (up from ₹0.72 loss in 3Q 2024). Revenue: ₹55.0m (up 59% from 3Q 2024). Net income: ₹3.06m (up ₹10.5m from 3Q 2024). Profit margin: 5.6% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.お知らせ • Jan 31Aspira Pathlab & Diagnostics Limited to Report Q3, 2025 Results on Feb 07, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2025 results on Feb 07, 2025お知らせ • Jan 22Aspira Pathlab & Diagnostics Limited Announces Resignation of Avinash Mahajan as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited informed that Mr. Avinash Mahajan has tendered his resignation as Non-Executive, Independent Director of the Company. Consequently, he also ceases to be the member of Audit Committee, Stakeholder Relationship Committee and Chairman of the Nomination & Remuneration Committee of the Company. Reason for change: Mr. Avinash Mahajan shall be completing 75 years of age on July 05, 2025. Pursuant to applicability of Regulation 17(1A) of SEBI (LODR) Regulations,2015 and consistent with the principles of good corporate governance, Mr. Avinash Mahajan has tendered his resignation as an Independent director and accordingly from Board Committees effective immediately. Mr. Avinash Mahajan has confirmed that there are no material reasons for his resignation. Date of cessation: January 22, 2025.New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$10m (₹680.1m market cap, or US$8.01m). Minor Risk Revenue is less than US$5m (₹152m revenue, or US$1.8m).お知らせ • Oct 31Aspira Pathlab & Diagnostics Limited to Report Q2, 2025 Results on Nov 12, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2025 results on Nov 12, 2024お知らせ • Aug 26Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024, at 12:00 Indian Standard Time.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.05 (vs ₹0.70 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.05 (up from ₹0.70 loss in 1Q 2024). Revenue: ₹47.3m (up 82% from 1Q 2024). Net income: ₹471.0k (up ₹7.63m from 1Q 2024). Profit margin: 1.0% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.お知らせ • Aug 03Aspira Pathlab & Diagnostics Limited to Report Q1, 2025 Results on Aug 13, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • May 30Full year 2024 earnings released: ₹2.60 loss per share (vs ₹0.086 loss in FY 2023)Full year 2024 results: ₹2.60 loss per share (further deteriorated from ₹0.086 loss in FY 2023). Revenue: ₹136.3m (down 5.9% from FY 2023). Net loss: ₹26.7m (loss widened ₹25.8m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.お知らせ • May 20Aspira Pathlab & Diagnostics Limited to Report Q4, 2024 Results on May 28, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2024 results on May 28, 2024Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹0.72 loss per share (vs ₹0.43 profit in 3Q 2023)Third quarter 2024 results: ₹0.72 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹35.6m (down 19% from 3Q 2023). Net loss: ₹7.42m (down 268% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Feb 13Aspira Pathlab & Diagnostics Limited Announces Resignation of Arvind Bhanushali as Non-Executive, Non-Independent Director and as Member of Audit CommitteeAspira Pathlab & Diagnostics Limited informed that Mr. Arvind Bhanushali Non-Executive, Non-Independent Director and as a member of Audit Committee of the Company, has tendered his resignation from the services of the Company due to personal reasons. He shall be relieved from his duties with effect from the close of business hours of February 13, 2024.お知らせ • Feb 02Aspira Pathlab & Diagnostics Limited to Report Q3, 2024 Results on Feb 10, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2024 results on Feb 10, 2024New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹370.0m market cap, or US$4.45m). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (₹141m revenue, or US$1.7m).お知らせ • Oct 28Aspira Pathlab & Diagnostics Limited to Report Q2, 2024 Results on Nov 11, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2024 results on Nov 11, 2023お知らせ • Oct 18Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as the Member of Nomination and Remuneration CommitteeAspira Pathlab & Diagnostics Limited has appointed Mr. Manas Mengar Independent Director of the Company as the member of Nomination and Remuneration Committee of the Company with effect from October 17, 2023. Name of the Directors: Mr. Avinash Chander Mahajan; Chairman of Nomination and Remuneration Committee; Independent Director, Mrs. Mangala Radha Krishnan Prabhu; Member of Nomination and Remuneration Committee; Independent Director, Mr. Manas Mengar; Member of Nomination and Remuneration Committee; Independent Director.お知らせ • Sep 29Aspira Pathlab & Diagnostics Limited Announces Completion of Tenure of Subhash Raghunath Salunke as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited announced that Mr. Subhash Raghunath Salunke (DIN: 07940567), Non-Executive and Independent Director of the Company has attained age of Seventy Five (75) years on April 19, 2023 and on the completion of his tenure as approved by the member by special resolution as per regulation 17(1A) of the Listing Regulation in the 49th Annual General Meeting of the Company till September 28, 2023, Consequently he ceases to hold Directorship of the Company, Member of the Audit Committee and Nomination and Remuneration Committee with effect from the closure of business hours on September 28, 2023. As per regulation 17(1A) of the Listing Regulation, he ceases to hold the following positions in the Company: Non-Executive and Independent Director, Member of the Audit Committee, Member of the Nomination and Remuneration Committee.お知らせ • Sep 28Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited appointed Manas Mengar as Non-Executive and Independent Director of the Company for a period of 5 (Five) consecutive years in compliance of applicable provisions of Companies Act, 2013 and Listing Regulations. Mr. Manas Mengar has completed his medical educational qualification in MBBS, DNB (Respiratory Diseases), D.M. Pulmonary and Critical Care Medicine. Currently he is serving as a consultant chest Physician, in Jupiter Hospital, Thane and Consultant Intensivist, in Padmashree Hospital, Dombivali. Maharashtra.お知らせ • Aug 15Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023, at 12:00 Indian Standard Time.Reported Earnings • Aug 13First quarter 2024 earnings released: ₹0.70 loss per share (vs ₹0.28 loss in 1Q 2023)First quarter 2024 results: ₹0.70 loss per share (further deteriorated from ₹0.28 loss in 1Q 2023). Revenue: ₹27.0m (down 8.9% from 1Q 2023). Net loss: ₹7.16m (loss widened 151% from 1Q 2023).お知らせ • Aug 13Aspira Pathlab & Diagnostics Limited Announces Appointment of Krupali Shah as Company Secretary Cum Compliance OfficerPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), Aspira Pathlab & Diagnostics Limited announced that, based on the recommendation of Nomination and Remuneration Committee and the Board of Directors of the Company at its meeting held August 12, 2023 has considered and approved: Appointment of Ms. Krupali Shah as the Company Secretary cum Compliance Officer of the Company. Ms. Krupali Shah (Membership No: A70473) is an Associate Member of the Institute of Company Secretaries of India and a Commerce Graduate from Mumbai University. She has overall experience of 4.5 years in the field of SEBI, Secretarial, Fema laws etc.お知らせ • Jul 28Aspira Pathlab & Diagnostics Limited to Report Q1, 2024 Results on Aug 12, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2024 results on Aug 12, 2023お知らせ • Jun 26Aspira Pathlab & Diagnostics Limited Announces the Resignation of Priya Pandey as Company Secretary and Compliance Officer, Key Managerial PersonnelAspira Pathlab & Diagnostics Limited announced that Ms Priya Pandey (Membership No. A66213), Company Secretary and Compliance Officer, Key Managerial Personnel (KMP) of the Company, vide her letter dated June 24, 2023, has tendered her resignation from the services of the Company. She shall be relieved of her duties with effect from the close of business hours of Saturday, June 24, 2023. The Company is in the process of appointing a successor for the position of Company Secretary and Compliance Officer, which shall be duly intimated to the Stock Exchange in due course.Reported Earnings • May 30Full year 2023 earnings released: ₹0.09 loss per share (vs ₹4.33 profit in FY 2022)Full year 2023 results: ₹0.09 loss per share (down from ₹4.33 profit in FY 2022). Revenue: ₹147.8m (down 24% from FY 2022). Net loss: ₹887.0k (down 102% from profit in FY 2022).Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be ₹39.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable.Buying Opportunity • Mar 16Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be ₹38.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.84 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.43 (down from ₹0.84 in 3Q 2022). Revenue: ₹44.9m (down 5.1% from 3Q 2022). Net income: ₹4.41m (down 49% from 3Q 2022). Profit margin: 9.8% (down from 18% in 3Q 2022). The decrease in margin was primarily driven by lower revenue.お知らせ • Feb 07Aspira Pathlab & Diagnostics Limited to Report Q3, 2023 Results on Feb 14, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2023 results on Feb 14, 2023Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 13Aspira Pathlab & Diagnostics Limited Approves the Change in Designation of Arvind Bhanushali from Executive Director to Non-Executive DirectorAspira Pathlab & Diagnostics Limited informed that Board of Directors of the Company, at their meeting held on November 12, 2022, considered and approved the change in Designation of Mr. Arvind Bhanushali from Executive Director to Non-Executive Director on the Board of the Company with effect from November 12, 2022.お知らせ • Nov 06Aspira Pathlab & Diagnostics Limited to Report Q2, 2023 Results on Nov 12, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2023 results on Nov 12, 2022Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 28x in the Healthcare industry in India. Total loss to shareholders of 38% over the past year.Recent Insider Transactions • Sep 25Insider recently sold ₹410k worth of stockOn the 23rd of September, Paresh Bhanushali sold around 10k shares on-market at roughly ₹41.01 per share. This transaction amounted to 6.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 25x in the Healthcare industry in India. Total loss to shareholders of 4.2% over the past year.お知らせ • Jul 28Aspira Pathlab & Diagnostics Limited to Report Q1, 2023 Results on Aug 13, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2023 results on Aug 13, 2022Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹53.70, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 25x in the Healthcare industry in India. Total returns to shareholders of 48% over the past year.お知らせ • May 21Aspira Pathlab & Diagnostics Limited to Report Q4, 2022 Results on May 28, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2022 results on May 28, 2022Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 17Aspira Pathlab & Diagnostics Limited Approves Appointment of Priya Pandey as Company Secretary and Compliance Officer of the CompanyAspira Pathlab & Diagnostics Limited at its board meeting held on April 16, 2022 approved the appointment of Ms. Priya Pandey as Company Secretary and Compliance Officer of the company with effect from April 16, 2022.Executive Departure • Oct 03Company Secretary & Compliance Officer Devyangi Patel has left the companyOn the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months.Executive Departure • Sep 29Company Secretary & Compliance Officer Devyangi Patel has left the companyOn the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months.お知らせ • Feb 06Aspira Pathlab & Diagnostics Limited to Report Q3, 2021 Results on Feb 13, 2021Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2021 results on Feb 13, 2021お知らせ • Jan 15Aspira Pathlab & Diagnostics Limited Announces Resignation of Mamta Mav as Company Secretary & Compliance OfficerAspira Pathlab & Diagnostics Limited announced that Ms. Mamta Mav, have resigned from the position of Company Secretary & Compliance Officer of the Company with effect from closing hours of January 14, 2021.お知らせ • Jul 26Aspira Pathlab & Diagnostics Limited to Report Q1, 2021 Results on Jul 28, 2020Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2021 results on Jul 28, 2020収支内訳Aspira Pathlab & Diagnostics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BSE:540788 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 2625010031 Dec 25242143030 Sep 25245333030 Jun 25226240031 Mar 25220203031 Dec 2420083030 Jun 24152-190031 Mar 24132-273031 Dec 23128-245030 Jun 23141-50031 Mar 23145-15031 Dec 22165162030 Sep 22168202030 Jun 22166220031 Mar 22195452031 Dec 21182344030 Sep 21177284030 Jun 21196400031 Mar 21152144031 Dec 20131-45030 Sep 20111-165030 Jun 2080-380031 Mar 2084-425031 Dec 1985-420030 Sep 1984-449030 Jun 1981-490031 Mar 1976-521031 Mar 1844-568031 Mar 178-2760質の高い収益: 540788は 高品質の収益 を持っています。利益率の向上: 540788の現在の純利益率 (0.2%)は、昨年(9.2%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 540788過去 5 年間で収益を上げており、収益は年間-21%増加しています。成長の加速: 540788は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 540788は過去 1 年間で収益成長率がマイナス ( -97.5% ) となったため、 Healthcare業界平均 ( 18.9% ) と比較することが困難です。株主資本利益率高いROE: 540788の 自己資本利益率 ( 0.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 11:46終値2026/06/12 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aspira Pathlab & Diagnostics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18Aspira Pathlab & Diagnostics Limited to Report Q4, 2026 Results on May 23, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 23, 2026
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹1.52 loss per share (vs ₹0.30 profit in 3Q 2025)Third quarter 2026 results: ₹1.52 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹52.5m (down 2.9% from 3Q 2025). Net loss: ₹15.6m (down ₹18.7m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 04Aspira Pathlab & Diagnostics Limited to Report Q3, 2026 Results on Feb 10, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2026 results on Feb 10, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹1.78 (vs ₹0.30 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.78 (up from ₹0.30 in 2Q 2025). Revenue: ₹82.3m (up 52% from 2Q 2025). Net income: ₹18.4m (up 500% from 2Q 2025). Profit margin: 22% (up from 5.7% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 04Aspira Pathlab & Diagnostics Limited to Report Q2, 2026 Results on Nov 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2026 results on Nov 12, 2025
Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.41 (up from ₹0.05 in 1Q 2025). Revenue: ₹53.6m (up 16% from 1Q 2025). Net income: ₹4.22m (up ₹3.74m from 1Q 2025). Profit margin: 7.9% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
New Risk • May 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.2% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.2% net profit margin). Revenue is less than US$5m (₹255m revenue, or US$2.7m). Market cap is less than US$100m (₹1.17b market cap, or US$12.2m).
お知らせ • May 18Aspira Pathlab & Diagnostics Limited to Report Q4, 2026 Results on May 23, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 23, 2026
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹77.07, the stock trades at a trailing P/E ratio of 55.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 141% over the past three years.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹64.74, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 97% over the past three years.
New Risk • Mar 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$10m (₹644.1m market cap, or US$7.01m). Minor Risk Revenue is less than US$5m (₹242m revenue, or US$2.6m).
お知らせ • Mar 07Aspira Pathlab & Diagnostics Limited Announces Resignation of Krupali Shah as Company Secretary Cum Compliance Officer, Effective March 8, 2026Aspira Pathlab & Diagnostics Limited has announced that Ms. Krupali Shah, (Membership No: A70473) Company Secretary cum Compliance Officer of the Company has tendered her resignation due to personal reasons and she will be relieved from her services with effect from March 8, 2026.
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹1.52 loss per share (vs ₹0.30 profit in 3Q 2025)Third quarter 2026 results: ₹1.52 loss per share (down from ₹0.30 profit in 3Q 2025). Revenue: ₹52.5m (down 2.9% from 3Q 2025). Net loss: ₹15.6m (down ₹18.7m from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 07Aspira Pathlab & Diagnostics Limited Appoints Kiran Raghavendra Awasthi as Non-Executive, Independent Director Effective November 12, 2025Aspira Pathlab & Diagnostics Limited has appointed Mrs. Kiran Raghavendra Awasthi (DIN: 09066721) as Non-Executive, Independent Director for the first term of five consecutive years with effect from November 12, 2025. The appointment was approved by the members of the company through Postal Ballot (remote e-voting) by a Special Resolution. Mrs. Kiran Awasthi is a Chartered Accountant and is a senior partner at AMRG & Associates with over 28 years of experience in the field of Finance, Audit, Accounting & Taxation. She also serves on Board of Raj Oil Mills Limited as Independent Director. She has wide and rich exposure in financial management, governance and analytical leadership with a strong commitment to professionalism and integrity.
お知らせ • Feb 04Aspira Pathlab & Diagnostics Limited to Report Q3, 2026 Results on Feb 10, 2026Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2026 results on Feb 10, 2026
お知らせ • Jan 05Aspira Pathlab & Diagnostics Limited Announces Demise of Independent Director Dr. Alaka Keshav Deshpande and Changes in Board Committee Composition, Effective on December 30, 2025Aspira Pathlab & Diagnostics Limited announced the demise of Dr. Alaka Keshav Deshpande, Independent Director aged 79 years, who passed away on December 30, 2025. Owing to the unfortunate demise of Dr. Alaka Keshav Deshpande, she ceases from the office of Independent Director of the Company effective from December 30, 2025 and also ceases the Membership held in the following Committees of Board: Audit Committee - Member, Nomination & Remuneration Committee - Member, Stakeholder Relationship Committee - Member.
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹1.78 (vs ₹0.30 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.78 (up from ₹0.30 in 2Q 2025). Revenue: ₹82.3m (up 52% from 2Q 2025). Net income: ₹18.4m (up 500% from 2Q 2025). Profit margin: 22% (up from 5.7% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 04Aspira Pathlab & Diagnostics Limited to Report Q2, 2026 Results on Nov 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2026 results on Nov 12, 2025
Valuation Update With 7 Day Price Move • Oct 03Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹71.68, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 45x in the Healthcare industry in India. Total returns to shareholders of 57% over the past three years.
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹702.7m market cap, or US$7.92m). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Revenue is less than US$5m (₹226m revenue, or US$2.5m).
お知らせ • Sep 26Aspira Pathlab & Diagnostics Limited Appoints Dr. Alaka Deshpande as Independent DirectorAspira Pathlab & Diagnostics Limited announced that at its AGM held on September 26, 2025, shareholders approved the appointment of Dr. Alaka Deshpande as independent director for the term of 3 years.
お知らせ • Sep 01Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2025, at 14:00 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2026 earnings released: EPS: ₹0.41 (vs ₹0.05 in 1Q 2025)First quarter 2026 results: EPS: ₹0.41 (up from ₹0.05 in 1Q 2025). Revenue: ₹53.6m (up 16% from 1Q 2025). Net income: ₹4.22m (up ₹3.74m from 1Q 2025). Profit margin: 7.9% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Aug 02Aspira Pathlab & Diagnostics Limited to Report Q1, 2026 Results on Aug 12, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹61.95, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹61.80, the stock trades at a trailing P/E ratio of 31.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 18% over the past three years.
Reported Earnings • May 20Full year 2025 earnings released: EPS: ₹1.97 (vs ₹2.60 loss in FY 2024)Full year 2025 results: EPS: ₹1.97 (up from ₹2.60 loss in FY 2024). Revenue: ₹223.9m (up 70% from FY 2024). Net income: ₹20.2m (up ₹46.9m from FY 2024). Profit margin: 9.0% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹548.1m market cap, or US$6.41m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (₹200m revenue, or US$2.3m).
お知らせ • May 10Aspira Pathlab & Diagnostics Limited to Report Q4, 2025 Results on May 16, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2025 results on May 16, 2025
Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.72 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.30 (up from ₹0.72 loss in 3Q 2024). Revenue: ₹55.0m (up 59% from 3Q 2024). Net income: ₹3.06m (up ₹10.5m from 3Q 2024). Profit margin: 5.6% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 31Aspira Pathlab & Diagnostics Limited to Report Q3, 2025 Results on Feb 07, 2025Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2025 results on Feb 07, 2025
お知らせ • Jan 22Aspira Pathlab & Diagnostics Limited Announces Resignation of Avinash Mahajan as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited informed that Mr. Avinash Mahajan has tendered his resignation as Non-Executive, Independent Director of the Company. Consequently, he also ceases to be the member of Audit Committee, Stakeholder Relationship Committee and Chairman of the Nomination & Remuneration Committee of the Company. Reason for change: Mr. Avinash Mahajan shall be completing 75 years of age on July 05, 2025. Pursuant to applicability of Regulation 17(1A) of SEBI (LODR) Regulations,2015 and consistent with the principles of good corporate governance, Mr. Avinash Mahajan has tendered his resignation as an Independent director and accordingly from Board Committees effective immediately. Mr. Avinash Mahajan has confirmed that there are no material reasons for his resignation. Date of cessation: January 22, 2025.
New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$10m (₹680.1m market cap, or US$8.01m). Minor Risk Revenue is less than US$5m (₹152m revenue, or US$1.8m).
お知らせ • Oct 31Aspira Pathlab & Diagnostics Limited to Report Q2, 2025 Results on Nov 12, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2025 results on Nov 12, 2024
お知らせ • Aug 26Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 27, 2024, at 12:00 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.05 (vs ₹0.70 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.05 (up from ₹0.70 loss in 1Q 2024). Revenue: ₹47.3m (up 82% from 1Q 2024). Net income: ₹471.0k (up ₹7.63m from 1Q 2024). Profit margin: 1.0% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 03Aspira Pathlab & Diagnostics Limited to Report Q1, 2025 Results on Aug 13, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • May 30Full year 2024 earnings released: ₹2.60 loss per share (vs ₹0.086 loss in FY 2023)Full year 2024 results: ₹2.60 loss per share (further deteriorated from ₹0.086 loss in FY 2023). Revenue: ₹136.3m (down 5.9% from FY 2023). Net loss: ₹26.7m (loss widened ₹25.8m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
お知らせ • May 20Aspira Pathlab & Diagnostics Limited to Report Q4, 2024 Results on May 28, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2024 results on May 28, 2024
Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹0.72 loss per share (vs ₹0.43 profit in 3Q 2023)Third quarter 2024 results: ₹0.72 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹35.6m (down 19% from 3Q 2023). Net loss: ₹7.42m (down 268% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Feb 13Aspira Pathlab & Diagnostics Limited Announces Resignation of Arvind Bhanushali as Non-Executive, Non-Independent Director and as Member of Audit CommitteeAspira Pathlab & Diagnostics Limited informed that Mr. Arvind Bhanushali Non-Executive, Non-Independent Director and as a member of Audit Committee of the Company, has tendered his resignation from the services of the Company due to personal reasons. He shall be relieved from his duties with effect from the close of business hours of February 13, 2024.
お知らせ • Feb 02Aspira Pathlab & Diagnostics Limited to Report Q3, 2024 Results on Feb 10, 2024Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2024 results on Feb 10, 2024
New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹370.0m market cap, or US$4.45m). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (₹141m revenue, or US$1.7m).
お知らせ • Oct 28Aspira Pathlab & Diagnostics Limited to Report Q2, 2024 Results on Nov 11, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2024 results on Nov 11, 2023
お知らせ • Oct 18Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as the Member of Nomination and Remuneration CommitteeAspira Pathlab & Diagnostics Limited has appointed Mr. Manas Mengar Independent Director of the Company as the member of Nomination and Remuneration Committee of the Company with effect from October 17, 2023. Name of the Directors: Mr. Avinash Chander Mahajan; Chairman of Nomination and Remuneration Committee; Independent Director, Mrs. Mangala Radha Krishnan Prabhu; Member of Nomination and Remuneration Committee; Independent Director, Mr. Manas Mengar; Member of Nomination and Remuneration Committee; Independent Director.
お知らせ • Sep 29Aspira Pathlab & Diagnostics Limited Announces Completion of Tenure of Subhash Raghunath Salunke as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited announced that Mr. Subhash Raghunath Salunke (DIN: 07940567), Non-Executive and Independent Director of the Company has attained age of Seventy Five (75) years on April 19, 2023 and on the completion of his tenure as approved by the member by special resolution as per regulation 17(1A) of the Listing Regulation in the 49th Annual General Meeting of the Company till September 28, 2023, Consequently he ceases to hold Directorship of the Company, Member of the Audit Committee and Nomination and Remuneration Committee with effect from the closure of business hours on September 28, 2023. As per regulation 17(1A) of the Listing Regulation, he ceases to hold the following positions in the Company: Non-Executive and Independent Director, Member of the Audit Committee, Member of the Nomination and Remuneration Committee.
お知らせ • Sep 28Aspira Pathlab & Diagnostics Limited Appoints Manas Mengar as Non-Executive and Independent DirectorAspira Pathlab & Diagnostics Limited appointed Manas Mengar as Non-Executive and Independent Director of the Company for a period of 5 (Five) consecutive years in compliance of applicable provisions of Companies Act, 2013 and Listing Regulations. Mr. Manas Mengar has completed his medical educational qualification in MBBS, DNB (Respiratory Diseases), D.M. Pulmonary and Critical Care Medicine. Currently he is serving as a consultant chest Physician, in Jupiter Hospital, Thane and Consultant Intensivist, in Padmashree Hospital, Dombivali. Maharashtra.
お知らせ • Aug 15Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023Aspira Pathlab & Diagnostics Limited, Annual General Meeting, Sep 26, 2023, at 12:00 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2024 earnings released: ₹0.70 loss per share (vs ₹0.28 loss in 1Q 2023)First quarter 2024 results: ₹0.70 loss per share (further deteriorated from ₹0.28 loss in 1Q 2023). Revenue: ₹27.0m (down 8.9% from 1Q 2023). Net loss: ₹7.16m (loss widened 151% from 1Q 2023).
お知らせ • Aug 13Aspira Pathlab & Diagnostics Limited Announces Appointment of Krupali Shah as Company Secretary Cum Compliance OfficerPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), Aspira Pathlab & Diagnostics Limited announced that, based on the recommendation of Nomination and Remuneration Committee and the Board of Directors of the Company at its meeting held August 12, 2023 has considered and approved: Appointment of Ms. Krupali Shah as the Company Secretary cum Compliance Officer of the Company. Ms. Krupali Shah (Membership No: A70473) is an Associate Member of the Institute of Company Secretaries of India and a Commerce Graduate from Mumbai University. She has overall experience of 4.5 years in the field of SEBI, Secretarial, Fema laws etc.
お知らせ • Jul 28Aspira Pathlab & Diagnostics Limited to Report Q1, 2024 Results on Aug 12, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2024 results on Aug 12, 2023
お知らせ • Jun 26Aspira Pathlab & Diagnostics Limited Announces the Resignation of Priya Pandey as Company Secretary and Compliance Officer, Key Managerial PersonnelAspira Pathlab & Diagnostics Limited announced that Ms Priya Pandey (Membership No. A66213), Company Secretary and Compliance Officer, Key Managerial Personnel (KMP) of the Company, vide her letter dated June 24, 2023, has tendered her resignation from the services of the Company. She shall be relieved of her duties with effect from the close of business hours of Saturday, June 24, 2023. The Company is in the process of appointing a successor for the position of Company Secretary and Compliance Officer, which shall be duly intimated to the Stock Exchange in due course.
Reported Earnings • May 30Full year 2023 earnings released: ₹0.09 loss per share (vs ₹4.33 profit in FY 2022)Full year 2023 results: ₹0.09 loss per share (down from ₹4.33 profit in FY 2022). Revenue: ₹147.8m (down 24% from FY 2022). Net loss: ₹887.0k (down 102% from profit in FY 2022).
Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be ₹39.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable.
Buying Opportunity • Mar 16Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be ₹38.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.84 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.43 (down from ₹0.84 in 3Q 2022). Revenue: ₹44.9m (down 5.1% from 3Q 2022). Net income: ₹4.41m (down 49% from 3Q 2022). Profit margin: 9.8% (down from 18% in 3Q 2022). The decrease in margin was primarily driven by lower revenue.
お知らせ • Feb 07Aspira Pathlab & Diagnostics Limited to Report Q3, 2023 Results on Feb 14, 2023Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2023 results on Feb 14, 2023
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 13Aspira Pathlab & Diagnostics Limited Approves the Change in Designation of Arvind Bhanushali from Executive Director to Non-Executive DirectorAspira Pathlab & Diagnostics Limited informed that Board of Directors of the Company, at their meeting held on November 12, 2022, considered and approved the change in Designation of Mr. Arvind Bhanushali from Executive Director to Non-Executive Director on the Board of the Company with effect from November 12, 2022.
お知らせ • Nov 06Aspira Pathlab & Diagnostics Limited to Report Q2, 2023 Results on Nov 12, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q2, 2023 results on Nov 12, 2022
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 28x in the Healthcare industry in India. Total loss to shareholders of 38% over the past year.
Recent Insider Transactions • Sep 25Insider recently sold ₹410k worth of stockOn the 23rd of September, Paresh Bhanushali sold around 10k shares on-market at roughly ₹41.01 per share. This transaction amounted to 6.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹44.10, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 25x in the Healthcare industry in India. Total loss to shareholders of 4.2% over the past year.
お知らせ • Jul 28Aspira Pathlab & Diagnostics Limited to Report Q1, 2023 Results on Aug 13, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2023 results on Aug 13, 2022
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹53.70, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 25x in the Healthcare industry in India. Total returns to shareholders of 48% over the past year.
お知らせ • May 21Aspira Pathlab & Diagnostics Limited to Report Q4, 2022 Results on May 28, 2022Aspira Pathlab & Diagnostics Limited announced that they will report Q4, 2022 results on May 28, 2022
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Executive Director Nikunj Mange was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 17Aspira Pathlab & Diagnostics Limited Approves Appointment of Priya Pandey as Company Secretary and Compliance Officer of the CompanyAspira Pathlab & Diagnostics Limited at its board meeting held on April 16, 2022 approved the appointment of Ms. Priya Pandey as Company Secretary and Compliance Officer of the company with effect from April 16, 2022.
Executive Departure • Oct 03Company Secretary & Compliance Officer Devyangi Patel has left the companyOn the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months.
Executive Departure • Sep 29Company Secretary & Compliance Officer Devyangi Patel has left the companyOn the 24th of September, Devyangi Patel's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Devyangi's name. A total of 6 executives have left over the last 12 months.
お知らせ • Feb 06Aspira Pathlab & Diagnostics Limited to Report Q3, 2021 Results on Feb 13, 2021Aspira Pathlab & Diagnostics Limited announced that they will report Q3, 2021 results on Feb 13, 2021
お知らせ • Jan 15Aspira Pathlab & Diagnostics Limited Announces Resignation of Mamta Mav as Company Secretary & Compliance OfficerAspira Pathlab & Diagnostics Limited announced that Ms. Mamta Mav, have resigned from the position of Company Secretary & Compliance Officer of the Company with effect from closing hours of January 14, 2021.
お知らせ • Jul 26Aspira Pathlab & Diagnostics Limited to Report Q1, 2021 Results on Jul 28, 2020Aspira Pathlab & Diagnostics Limited announced that they will report Q1, 2021 results on Jul 28, 2020